123
Participants
Start Date
June 6, 2018
Primary Completion Date
December 30, 2026
Study Completion Date
December 30, 2026
Runimotamab
Runimotamab will be administered via IV infusion until disease progression, intolerable toxicity, or any other discontinuation criteria are met.
Trastuzumab
Trastuzumab will be administered via IV infusion
Tocilizumab
Participants will receive IV tocilizumab if needed
Rigshospitalet-Blegdamsvej 9, Copenhagen
Peter MacCallum Cancer Centre, Melbourne
Grand Hopital de Charleroi asbl, Charleroi
Memorial Sloan Kettering Cancer Center, New York
National Taiwan University Hospital, Taipei
ASST Grande Ospedale Metropolitano Niguarda - Presidio Ospedaliero Ospedale Niguarda Ca' Granda, Milan
START MADRID_Hospital Universiario Fundacion Jimenez Diaz, Madrid
START MADRID_Hospital Universitario HM Sanchinarro - CIOCC - EDOS, Madrid
Hospital Universitario Quironsalud Madrid, Pozuelo de Alarcón
Institut Claudius Regaud, Toulouse
EDOG - Institut Bergonie - PPDS, Bordeaux
SCRI Oncology Partners, Nashville
China Medical University Hospital, Taichung
Hospital Clinico Universitario de Valencia, Valencia
Washington University, Saint Louis
Centre Léon Bérard, Lyon
MD Anderson Cancer Center, Houston
Gustave Roussy, Villejuif
National Cancer Centre, Singapore
Yale University, New Haven
Princess Margaret Hospital, Toronto
National Cancer Center East, Chiba
Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam
Asan Medical Center, Seoul
Seoul National University Hospital, Seoul
Hospital Universitari Vall d'Hebron, Barcelona
Churchill Hospital, Oxford
Lead Sponsor
Genentech, Inc.
INDUSTRY